Development of clinical screening tool for exocrine pancreatic insufficiency in patients with definite chronic pancreatitis
Pancreatology · 2024
DOI: 10.1016/j.pan.2024.04.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pancreatology, 2024. Verfasst von Mohamed O Othman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Baylor College of Medicine, Houston, TX, USA. Electronic address: Mohamed.Othman@bcm.edu. Hauptthemen laut MEDLINE: Pancreatitis, Chronic, Exocrine Pancreatic Insufficiency. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie Inc.
Abstract (Originalsprache)
BACKGROUND/OBJECTIVES: No simple, accurate diagnostic tests exist for exocrine pancreatic insufficiency (EPI), and EPI remains underdiagnosed in chronic pancreatitis (CP). We sought to develop a digital screening tool to assist clinicians to predict EPI in patients with definite CP. METHODS: This was a retrospective case-control study of patients with definite CP with/without EPI. Overall, 49 candidate predictor variables were utilized to train a Classification and Regression Tree (CART) model to rank all predictors and select a parsimonious set of predictors for EPI status. Five-fold cross-validation was used to assess generalizability, and the full CART model was compared with 4 additional predictive models. EPI misclassification rate (mRate) served as primary endpoint metric. RESULTS: 274 patients with definite CP from 6 pancreatitis centers across the United States were included, of which 58 % had EPI based on predetermined criteria. The optimal CART decision tree included 10 variables. The mRate without/with 5-fold cross-validation of the CART was 0.153 (training error) and 0.314 (prediction error), and the area under the receiver operating characteristic curve was 0.889 and 0.682, respectively. Sensitivity and specificity without/with 5-fold cross-validation was 0.888/0.789 and 0.794/0.535, respectively. A trained second CART without pancreas imaging variables (n = 6), yielded 8 variables. Training error/prediction error was 0.190/0.351; sensitivity was 0.869/0.650, and specificity was 0.728/0.649, each without/with 5-fold cross-validation. CONCLUSION: We developed two CART models that were integrated into one digital screening tool to assess for EPI in patients with definite CP and with two to six input variables needed for predicting EPI status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Baylor College of Medicine, Houston, TX, USA. Electronic address: Mohamed.Othman@bcm.edu.
- University of Florida, Gainesville, FL, USA.
- University of Pittsburgh, Pittsburgh, PA, USA.
- Johns Hopkins University, Baltimore, MD, USA.
- Ohio State University, Columbus, OH, USA.
- Stanford University, Stanford, CA, USA.
Förderung
- AbbVie Inc
Zitieren
APA
Othman, M. O., Forsmark, C., Yadav, D., Singh, V. K., Lara, L. F., Park, W., Zhang, Z., Yu, J., & Kort, J. J. (2024). Development of clinical screening tool for exocrine pancreatic insufficiency in patients with definite chronic pancreatitis. Pancreatology. https://doi.org/10.1016/j.pan.2024.04.003
Vancouver
Othman MO, Forsmark C, Yadav D, Singh VK, Lara LF, Park W, et al. Development of clinical screening tool for exocrine pancreatic insufficiency in patients with definite chronic pancreatitis. Pancreatology. 2024. doi:10.1016/j.pan.2024.04.003
BibTeX
@article{Othman2024,
author = {Othman, Mohamed O and Forsmark, Christopher and Yadav, Dhiraj and Singh, Vikesh K and Lara, Luis F and Park, Walter and Zhang, Zuoyi and Yu, Jun and Kort, Jens J},
title = {Development of clinical screening tool for exocrine pancreatic insufficiency in patients with definite chronic pancreatitis},
journal = {Pancreatology},
year = {2024},
doi = {10.1016/j.pan.2024.04.003}
}
EUVIMED